Cargando…

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer

PURPOSE: In estrogen receptor-positive (ER+) breast cancer models, activation of Aurora A kinase (AURKA) is associated with downregulation of ERα expression and resistance to endocrine therapy. Alisertib is an oral selective inhibitor of AURKA. The primary objectives of this phase I trial were to de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haddad, Tufia C., D’Assoro, Antonino, Suman, Vera, Opyrchal, Mateusz, Peethambaram, Prema, Liu, Minetta C., Goetz, Matthew P., Ingle, James N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842248/ https://www.ncbi.nlm.nih.gov/pubmed/29289986 http://dx.doi.org/10.1007/s10549-017-4616-7

Ejemplares similares

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
por: Haddad, Tufia C., et al.
Publicado: (2023)

Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells
por: Opyrchal, Mateusz, et al.
Publicado: (2014)

Aurora-A Kinase as a Promising Therapeutic Target in Cancer
por: D’Assoro, Antonino B., et al.
Publicado: (2016)

Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells
por: Opyrchal, Mateusz, et al.
Publicado: (2017)

Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells
por: Ohmine, Seiga, et al.
Publicado: (2018)

Inhibition of Cdk2 kinase activity selectively targets the CD44(+)/CD24(−/Low) stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells
por: OPYRCHAL, MATEUSZ, et al.
Publicado: (2014)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance
por: Jalalirad, Mohammad, et al.
Publicado: (2021)

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
por: Bachelot, Thomas, et al.
Publicado: (2013)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

NOTCH3 expression is linked to breast cancer seeding and distant metastasis
por: Leontovich, Alexey A., et al.
Publicado: (2018)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
por: Garnett, Sally Anne, et al.
Publicado: (2013)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
por: Lindeman, Geoffrey J., et al.
Publicado: (2022)

Roles of Notch Signaling in the Tumor Microenvironment
por: D’Assoro, Antonino B., et al.
Publicado: (2022)

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
por: Sanft, Tara, et al.
Publicado: (2015)

Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients—a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy
por: Kuhn, Elaine P., et al.
Publicado: (2023)

Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells
por: LEONTOVICH, ALEXEY A., et al.
Publicado: (2013)

Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy
por: Iankov, Ianko D., et al.
Publicado: (2015)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
por: Nguyen, Rosa, et al.
Publicado: (2022)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
por: Ahlin, Cecilia, et al.
Publicado: (2017)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
por: Xu, Liang, et al.
Publicado: (2018)

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
por: Hancock, G. R., et al.
Publicado: (2022)

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
por: Chen, Tom Wei-Wu, et al.
Publicado: (2023)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_fm61hvb2pcn2smooasuhbfsk51